Gilead Sciences, Inc.

Pari Gmbh

Pari Pharma Gmbh

Frank-Christophe Lintz

Manfred Keller

Alan Bruce Montgomery

Jurgen Jauernig

Ingo Friedrich

A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused byspecies,as well as those caused by, and multidrug resistant, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.

Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections

Sterile compositions for administration as aerosols are described. They contain an active agent which is poorly water-soluble, a non-ionic surfactant acomponent and a phospholipid component. The compositions are suitable for oral or nasal inhalation, but also for topical or oromucosal administration. They are particulary useful for the efficient pulmonary administration of poorly soluble corticosteroids and can be aerosolized with common nebulizers.

Pharmaceutical aerosol composition

Growing community of inventors

Starnberg, Germany

Frank-Christophe Lintz